The launch of Sound Bioventures Fund I resulted in broad coverage of the international life science trade media and Scandinavian financial press. Our strategy to invest in clinical, or near clinical, private companies in niche/rare indications were well presented. As Bibhash put it in Biocentury “We’ll go to the best company in the space that’s about to go clinical!”.
Broad Media Coverage of the launch of Sound Bioventures Fund I
![](https://soundbioventures.com/wp-content/uploads/2022/01/Media-Coverage-Sound-Bioventures-Inaugeration.png)
Navigating the journey of orphan drug development
You must be logged in to view this page.
NephroDI Therapeutics Announces Investment by Sound Bioventures to Accelerate Development of NDI-5001 as a Potential First-in-Class Therapy for Pediatric Orphan Kidney Disease
You must be logged in to view this page.
Sound Bioventures: Putting Scandinavian Biotechs on the Global Stage
You must be logged in to view this page.
Evolving to the next phase of viral therapy development
You must be logged in to view this page.